Epizyme Partner Spotlight
Dr John P. Leonard discusses the complex landscape and management of patients with lymphoma, as well as hot topics in hematologic malignancies, including the use of monsunetuzumab therapy.
A phase III trial found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in radiographic progression-free survival...
This research works to advance the ability to create individualized therapy regimens and guide SCLC prognostication.
This study works to determine the demographic, histopathologic and clinical characteristics of cancer patients most impacted by COVID-19.
Treatment of LA-STS with the radio-enhancer NBTXR3 plus RT did not negatively impact quality of life or long-term morbidity, according to results of the phase 2/3 ACT.IN.SARC trial...
Some newer therapies are on the horizon for R/R DLBCL and offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and CAR T-cell therapy.